Novo Nordisk announced it will cut 9,000 jobs due to lowered profit guidance and increased competition in the obesity drug market, particularly affecting its products Ozempic and Wegovy. The company aims to save DKK8 billion annually by 2026 and has lowered its profit growth forecast. CEO Mike Doustdar acknowledged the competitive landscape, especially against rivals like Eli Lilly. The job cuts are seen as a response to strategic setbacks and disappointing drug trials. Teljes cikk (Euronews.com)